CRISPR-Cas systems, derived from prokaryotic adaptive immunity, represent a revolutionary advancement in genetic engineering.  These systems utilize a guide RNA (gRNA) molecule to direct the Cas nuclease, most commonly Cas9, to a specific DNA target sequence.  The Cas enzyme then generates a double-strand break (DSB) at the targeted locus.  Cellular DNA repair mechanisms, namely non-homologous end joining (NHEJ) and homology-directed repair (HDR), are subsequently engaged. NHEJ often introduces insertions or deletions, resulting in gene disruption, while HDR allows for precise gene editing through the introduction of a donor template.  This precision and relative simplicity have propelled CRISPR into widespread application across diverse fields.  However, challenges remain, including off-target effects resulting from gRNA mismatches and the efficiency of HDR, which often lags behind NHEJ. Ongoing research focuses on improving gRNA design, developing higher-fidelity Cas nucleases, and enhancing HDR efficiency to refine the accuracy and efficacy of CRISPR-mediated genome editing.  The continued development and optimization of CRISPR technology promises to significantly impact various sectors, including therapeutics, agriculture, and fundamental biological research.